Keys to Avoiding Pharmaceutical Supply Chain Problems in the COVID-19 Environment – Important Negotiating and Drafting Tips for Life Sciences Professionals and Attorneys
Thursday, July 16 , 2020
12:00 pm - 1:00 pm Eastern Time
11:00 am - 12:00 pm Central Time
10:00 am- 11:00 am Mountain Time
9:00 am - 10:00 am Pacific Time
One consequence of the COVID-19 pandemic is that many pharmaceutical and biotech companies are being required to address novel business issues, many of which were not contemplated by existing legal contracts and business arrangements. One of these issues is the impact of the pandemic on the global pharmaceutical drug supply chain. The purpose of this Webinar is to address some important supply agreement terms that a prudent pharmaceutical company decision-maker or attorney should consider, especially in light of the new COVID-19 landscape.
Following this Webinar, participants will be able to:
- identify various important issues that arise in negotiating and drafting supply agreements, especially in light of the COVID pandemic;
- analyze appropriate solutions to these issues; and
- defend these solutions when negotiating with adversaries.
Ira Rosenberg, Sills Cummis & Gross P.C., Chair, Life Sciences Practice Group
Ira A. Rosenberg is a senior partner at Sills Cummis & Gross and Co-Chair of the Corporate Practice Group and Chair of the Life Sciences Practice Group. Mr. Rosenberg has more than 30 years’ experience representing life science and healthcare technology companies, ranging in size from start-ups to public companies, in corporate and intellectual property transactions and general corporate matters. This work has included numerous product and technology acquisition, development, licensing, supply and distribution transactions, venture capital financings, mergers and acquisitions, strategic alliances and joint ventures. He has structured and negotiated corporate partnering transactions with numerous global and other large pharmaceutical companies. He has been recognized by being named by Chambers USA 2008-2020 for New Jersey Corporate/M&A, The Best Lawyers in America 1995-2020 for Corporate Law; Mergers and Acquisitions Law, IFLR1000 United States: Guide to USA’s Leading Financial and Corporate Law Firms 2018-2020 for “Highly Regarded” New Jersey M&A and New Jersey Super Lawyers 2005-2020 for Mergers & Acquisitions; Securities & Corporate Finance.
Lori Waldron, Sills Cummis & Gross P.C., Co-Chair, Life Sciences Practice Group
Lori M. Waldron is Co-Chair of the Sills Cummis & Gross Life Sciences Practice Group. Her practice focuses on the representation of both emerging growth and well-established public and private companies in sophisticated business transactions, with a particular emphasis on the life sciences and biotech industries. Ms. Waldron has personally represented clients in 200+ transactions and has significant experience advising clients through all phases of their business cycles. Her regular life sciences practice includes counseling clients regarding intellectual property licenses, joint ventures and strategic alliances, research and development agreements and supply, distribution and co-promote agreements. Ms. Waldron is well-published and has received numerous awards including New Jersey Law Journal Dealmaker of the Year – Mergers & Acquisitions 2019; IFLR1000 United States: Guide to USA’s Leading Financial & Corporate Law Firms 2018-2019, "Rising Star” New Jersey M&A; and NJBIZ Best 50 Women in Business 2019.
LES Members Price: FREE
(LESI Members please contact email@example.com for a code)
Want to view this and all LES webinars (recorded and LIVE) for free Join LES Today!
By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.